These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38511072)

  • 1. Prescribing patterns of SGLT-2 inhibitors for patients with heart failure: A two-center analysis.
    Chakrala T; Prakash RO; Kim J; Gao H; Ghaffar U; Patel J; Parker A; Dass B
    Am Heart J Plus; 2023 Apr; 28():100286. PubMed ID: 38511072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse effects of sodium-glucose cotransporter-2 inhibitors in patients with heart failure: a systematic review and meta-analysis.
    Pozzi A; Cirelli C; Merlo A; Rea F; Scangiuzzi C; Tavano E; Iorio A; Kristensen SL; Wong C; Iacovoni A; Corrado G
    Heart Fail Rev; 2024 Jan; 29(1):207-217. PubMed ID: 37917192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Qualitative Evaluation to Understand Barriers and Facilitators to Prescribing Angiotensin Receptor-Neprilysin Inhibitors (ARNi) and Sodium-Glucose Cotransporter Inhibitors (SGLT2i) in Patients with Heart Failure with Reduced Ejection Fraction (HFrEF).
    Pradhan AM; Lussier M; Nguyen M; Voyce S; Wright EA
    J Am Pharm Assoc (2003); 2024 Aug; ():102224. PubMed ID: 39209218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
    Gonzalez J; Bates BA; Setoguchi S; Gerhard T; Dave CV
    Cardiovasc Diabetol; 2023 Mar; 22(1):54. PubMed ID: 36899387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Cardiovascular Outcomes in Patients with Diabetes Mellitus and Heart Failure.
    Hofer F; Kazem N; Richter B; Sulzgruber P; Schweitzer R; Pailer U; Hammer A; Koller L; Hengstenberg C; Niessner A
    Cardiovasc Drugs Ther; 2022 Jun; 36(3):497-504. PubMed ID: 34342791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?
    Al Rifai M; Newby LK; Nair AP; Misra A; Rogers JG; Fedson S; Virani SS
    Curr Atheroscler Rep; 2022 Aug; 24(8):627-634. PubMed ID: 35653033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-Glucose Cotransporter 2 Inhibitors Among Heart Failure With Mildly Reduced and Preserved Ejection Fraction.
    Cheng JWM; Colucci V; Kalus JS; Spinler SA
    Ann Pharmacother; 2023 Nov; 57(11):1291-1301. PubMed ID: 36800904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis.
    Hinton W; Feher MD; Munro N; Joy M; de Lusignan S
    Cardiovasc Diabetol; 2021 Jun; 20(1):130. PubMed ID: 34183018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure.
    Ji PJ; Zhang ZY; Yan Q; Cao HL; Zhao YJ; Yang B; Li J
    ESC Heart Fail; 2023 Apr; 10(2):1314-1325. PubMed ID: 36722326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Emerging Role of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure.
    Gitto M; Villaschi A; Federici M; Condorelli G; Stefanini GG
    Curr Pharm Des; 2023; 29(7):481-493. PubMed ID: 36799420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescription patterns of diabetes medications influencing clinical outcomes of heart failure patients with reduced ejection fraction.
    Chang HY; Su YW; Feng AN; Fong MC; Huang KC; Chong E; Chen KC; Yin WH
    ESC Heart Fail; 2020 Apr; 7(2):604-615. PubMed ID: 31995274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Inpatient Initiation of Sodium-Glucose Cotransporter-2 Inhibitors on Prescription Rates in Patients With Heart Failure With Reduced Ejection Fraction.
    Okoroike H; Patel S; Simone P; Lavelle R; Szwak JA
    Am J Cardiol; 2023 Jan; 186():150-155. PubMed ID: 36283884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety outcomes of SGLT2i in the heart failure trials: A systematic review and Meta-analysis.
    Younes AM; Salem M; Maraey A; Nomigolzar S; Sewell K; Khalil M; Elzanaty A; Saeyeldin A; Dar M
    Int J Cardiol; 2022 Nov; 366():51-56. PubMed ID: 35777490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
    Mentz RJ; Brunton SA; Rangaswami J
    Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How Would You Manage This Patient With Heart Failure With Preserved Ejection Fraction? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Smetana GW; Ho JE; Orkaby AR; Reynolds EE
    Ann Intern Med; 2023 Dec; 176(12):1656-1665. PubMed ID: 38079640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials.
    Lu Y; Li F; Fan Y; Yang Y; Chen M; Xi J
    Eur J Intern Med; 2021 May; 87():20-28. PubMed ID: 33824055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.
    Butler J; Handelsman Y; Bakris G; Verma S
    Eur J Heart Fail; 2020 Apr; 22(4):604-617. PubMed ID: 31926059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
    Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure With Preserved Ejection Fraction and Diabetes.
    Enzan N; Matsushima S; Kaku H; Tohyama T; Nagata T; Ide T; Tsutsui H
    JACC Asia; 2023 Feb; 3(1):93-104. PubMed ID: 36873765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.